Research programme: nucleic acid therapeutics - ANRis Pharma

Drug Profile

Research programme: nucleic acid therapeutics - ANRis Pharma

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator ANRis Pharma
  • Class Macromolecular substances; Nucleic acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer; Kidney disorders

Most Recent Events

  • 15 Sep 2015 Early research in Cancer in Canada (unspecified route)
  • 15 Sep 2015 Research programme: nucleic acid therapeutics - ANRis Pharma is available for licensing as of 15 Sep 2015. http://anrispharma.com/
  • 15 Sep 2015 Early research in Kidney disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top